Action Selvita - 0RKT

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

57,00

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

0,00

0,00 Fourchette du Jour 0,00

57,00 Plage de 52 semaines 57,00

Cap du marché

1,318B

Clôture Veille

57,00

Ouverture

Dernière Transaction

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

0,00

Actions en circulation

23 120 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-14,31

Bénéfice par action (BPA)

-3,98

Chiffre d'affairess

67,99M

Bénéfice net

-92,11M

Secteur

Chemicals & Chem Preps, Nec

Industrie

Chemicals & Chem Preps, Nec

Site Web

ryvu.com

Siège social

Krakow, Pol

Fondé

Selvita Sa est coté dans le secteur Chemicals & Chem Preps de la London Stock Exchange avec le ticker 0RKT. Le dernier cours de clôture d'Selvita était de PLN57,00. Au cours de la dernière année, les actions de Selvita ont été négociées dans une fourchette de prix de PLN 57,00 à PLN 57,00.

Selvita compte actuellement 23 120 000 actions en circulation. La capitalisation boursière d'Selvita est de PLN1,32 milliard. Selvita a un ratio cours/bénéfice (ratio PE) de -14.31.

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium PR Newswire KRAKOW, Poland, Oct. 23, 2024...

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium PR Newswire KRAKOW, Poland, Oct. 9, 2024...

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit PR Newswire KRAKOW, Poland, Sept. 23, 2024 ONCO Prime is a cutting-edge drug discovery...

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress PR Newswire KRAKOW, Poland, June 14, 2024 RVU120 as a single agent showed...

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting PR Newswire KRAKOW, Poland, March 6, 2024 Updated preclinical data will be...

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS PR Newswire KRAKOW...

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting PR Newswire KRAKOW, Poland, Nov. 2, 2023 Updated data from the Phase I trial of RVU120...

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update PR Newswire KRAKOW, Poland, Sept. 28, 2022 KRAKOW, Poland, Sept. 28, 2022 /PRNewswire/ -- Ryvu...

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress PR Newswire KRAKOW, Poland, June 10, 2022 - Clinically...

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting PR Newswire KRAKOW, Poland, March 8, 2022 KRAKOW, Poland, March 8, 2022 /PRNewswire/ -- Ryvu Therapeutics...

Période	Ouver.	Haut	Bas
1	57	57	57	DE
4	57	57	57	DE
12	57	57	57	DE
26	57	57	57	DE
52	57	57	57	DE
156	57	57	57	DE
260	57	57	57	DE

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
BLUBlue Star Capital Plc	0,025p (42,86%)	95,56M
SCGLSealand Capital Galaxy Limited	0,415p (38,33%)	13,62M
SCESurface Transforms Plc	0,34p (30,77%)	108,17M
IESInvinity Energy Systems Plc	14,75p (25,53%)	2,91M
CRTACirata Plc	33,00p (24,88%)	495,28k
UOGUnited Oil & Gas Plc	0,125p (-34,21%)	116,44M
SYSSysgroup Plc	21,50p (-24,56%)	512,48k
KEFIKefi Gold And Copper Plc	0,526p (-19,33%)	308,97M
GENLGenel Energy Plc	72,40p (-17,82%)	1,78M
KZGKazera Global Plc	1,075p (-14,00%)	1,25M
ORCPOracle Power Plc	0,0595p (4,39%)	2B
NTVONativo Resources Plc	0,0023p (-8,00%)	575,78M
KEFIKefi Gold And Copper Plc	0,526p (-19,33%)	308,97M
TRPTower Resources Plc	0,03p (1,69%)	133,16M
CLONClontarf Energy Plc	0,0335p (-10,67%)	117,55M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Selvita Sa (0RKT)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Selvita Sa

0RKT Dernières nouvelles

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Ouver.	Haut	Bas
1	57	57	57	DE
4	57	57	57	DE
12	57	57	57	DE
26	57	57	57	DE
52	57	57	57	DE
156	57	57	57	DE
260	57	57	57	DE

Période	Ouver.	Haut	Bas
1	57	57	57	DE
4	57	57	57	DE
12	57	57	57	DE
26	57	57	57	DE
52	57	57	57	DE
156	57	57	57	DE
260	57	57	57	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Selvita Sa (0RKT) Cours

Selvita Sa (0RKT)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Selvita Sa

0RKT Dernières nouvelles

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Ouver.	Haut	Bas
1	57	57	57	DE
4	57	57	57	DE
12	57	57	57	DE
26	57	57	57	DE
52	57	57	57	DE
156	57	57	57	DE
260	57	57	57	DE